Formulary
Hepatitis A and B vaccine: Indications, Dosing, Side Effects and Interactions
Hepatitis A and B vaccine clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 4 min read
Hepatitis A and B vaccine: Indications, Dosing, Side Effects and Interactions
Hepatitis A and B vaccine clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Immunisation against hepatitis A and hepatitis B infection [primary course]**
- **Child** (By Intramuscular Injection): 1-15 years Initially 0.5 mL every month for 2 doses, then 0.5 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Post-exposure prophylaxis against hepatitis A infection [**
- **Child** (By Intramuscular Injection): for rapid protection] 1-15 years 1 mL for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh may be used in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Immunisation against hepatitis A and hepatitis B infection [accelerated schedule**
- **Child** (By Intramuscular Injection): for travellers departing within 1 month] 16-17 years Initially 1 mL for 1 dose, then 1 mL after 7 days for 1 dose, then 1 mL after 14 days for 1 dose, then 1 mL for 1 dose given 12 months after the first dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
- **Adult** (By Intramuscular Injection): Initially 1 mL for 1 dose, then 1 mL after 7 days for 1 dose, then 1 mL after 14 days for 1 dose, then 1 mL for 1 dose given 12 months after the first dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Immunisation against hepatitis A and hepatitis B infection [primary course] for Ambirix**
- **Child 1-15 years** (By intramuscular injection): Initially 1 mL for 1 dose, then 1 mL after 6-12 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh may be used in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Post-exposure prophylaxis against hepatitis A infection [for rapid protection] for Ambirix**
- **Child 1-15 years** (By intramuscular injection): 1 mL for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh may be used in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Immunisation against hepatitis A and hepatitis B infection [primary course] for Twinrix Adult**
- **Child 16-17 years** (By intramuscular injection): Initially 1 mL every month for 2 doses, then 1 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Immunisation against hepatitis A and hepatitis B infection [accelerated schedule for travellers departing within 1 month] for Twinrix Adult**
- **Child 16-17 years** (By intramuscular injection): Initially 1 mL for 1 dose, then 1 mL after 7 days for 1 dose, then 1 mL after 14 days for 1 dose, then 1 mL for 1 dose given 12 months after the first dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
**Immunisation against hepatitis A and hepatitis B infection [primary course] for Twinrix Paediatric**
- **Child 1-15 years** (By intramuscular injection): Initially 0.5 mL every month for 2 doses, then 0.5 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced).
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Hepatitis A and B vaccine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary